Edition:
United States

Grifols SA (GRLS.MC)

GRLS.MC on Madrid SE C.A.T.S.

24.89EUR
20 Jul 2018
Change (% chg)

€-0.15 (-0.60%)
Prev Close
€25.04
Open
€25.00
Day's High
€25.12
Day's Low
€24.81
Volume
1,011,432
Avg. Vol
706,862
52-wk High
€28.07
52-wk Low
€21.50

Select another date:

Mon, May 14 2018

BRIEF-Grifols Expands Its Blood Typing Solutions Portfolio In US With Antisera Reagents

* GRIFOLS EXPANDS ITS BLOOD TYPING SOLUTIONS PORTFOLIO IN THE UNITED STATES WITH ANTISERA REAGENTS Source text for Eikon: Further company coverage: (Gdynia Newsroom)

BRIEF-Grifols Q1 EBITDA Down 2.8 Pct At 297 Mln Euros YoY

* Q1 EBITDA 297.4 MILLION EUROS VERSUS 306.0 MILLION EUROS YEAR AGO

BRIEF-Grifols Concludes Experimental Phase Of Clinical Trial On Alzheimer

* SAYS CONCLUDES EXPERIMENTAL PHASE OF AMBAR, A CLINICAL TRIAL ON ALZHEIMER'S DISEASE

BRIEF-Grifols To Buy German Pharmaceutical Company Haema For 220 Mln Euros

* SAYS REACHES DEAL WITH ATON GMBH TO BUY 100 PERCENT OF HAEMA AG FOR 220 MILLION EUROS ON A DEBT FREE BASIS ‍​ Source text for Eikon:

BRIEF-Grifols Announces New Agreement With Henry Schein To Distribute Normal Saline Solution In U.S.

* GRIFOLS - ANNOUNCES NEW AGREEMENT WITH HENRY SCHEIN TO DISTRIBUTE NORMAL SALINE SOLUTION IN THE U.S.

BRIEF-Grifols FY Net Profit Up At 662.7 Mln Euros

* FY NET SALES 4.32 BILLION EUROS VERSUS 4.05 BILLION EUROS YEAR AGO

BRIEF-Grifols Receives FDA Approval For New Formulation Of Its Rabies Virus Treatment

* GRIFOLS HYPERRAB® (RABIES IMMUNE GLOBULIN) 300 IU/ML RECEIVES FDA APPROVAL TO TREAT PATIENTS EXPOSED TO RABIES VIRUS INFECTION Source text for Eikon: Further company coverage: (Gdynia Newsroom)

BRIEF-Grifols Sees Positive Impact Of 90 Mln Euros In Q4 After Revaluation Of US Assets

* SEES POSITIVE NON-RECURRING IMPACT OF ABOUT 90 MILLION EUROS NET IN Q4 FROM US TAX REFORM AND REASSESSMENT OF ASSETS RELATED TO ARADIGM Source text for Eikon:

BRIEF-Grifols Buys 51 Pct Of Medkeeper

* SAYS PURCHASE RESULT OF $98 MLN CAPITAL INCREASE IN MEDKEEPER

Select another date: